Covered recipient · General Payments record
MERCEDES E GONZALEZ
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$28,485.25
89 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,035.00 | 7 |
| Consulting Fee | $11,397.00 | 12 |
| Food and Beverage | $1,897.93 | 68 |
| Education | $155.32 | 2 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $15,344.98 | 23 |
| GENZYME CORPORATION | $11,696.07 | 10 |
| Lilly USA, LLC | $265.90 | 7 |
| AbbVie Inc. | $207.07 | 8 |
| PFIZER INC. | $175.71 | 9 |
| Janssen Biotech, Inc. | $123.32 | 3 |
| LEO Pharma Inc. | $110.80 | 2 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $93.77 | 5 |
| SANOFI-AVENTIS U.S. LLC | $90.34 | 2 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $71.67 | 4 |
| Alexion Pharmaceuticals, Inc. | $42.52 | 2 |
| Incyte Corporation | $42.25 | 2 |
| Almirall LLC | $40.60 | 2 |
| Novartis Pharmaceuticals Corporation | $39.08 | 2 |
| Xeris Pharmaceuticals, Inc. | $32.40 | 2 |
| VYNE Pharmaceuticals Inc. | $26.96 | 1 |
| Galderma Laboratories, L.P. | $20.11 | 1 |
| TOLMAR Pharmaceuticals, Inc. | $18.04 | 1 |
| DERMIRA, INC. | $15.68 | 1 |
| Amneal Pharmaceuticals LLC | $14.99 | 1 |
| Biofrontera Inc. | $12.99 | 1 |
Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MERCEDES E GONZALEZ
NPI 1750563243 · CMS profile ID 306248
Allopathic & Osteopathic Physicians / Dermatology
MIAMI, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1750563243?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MERCEDES E GONZALEZ, NPI 1750563243, CMS profile ID 306248. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750563243?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). MERCEDES E GONZALEZ, NPI 1750563243, CMS profile ID 306248. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750563243?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- MERCEDES E GONZALEZ, NPI 1750563243, CMS profile ID 306248, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1750563243?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
89 matching records · $28,485.25 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–89 of 89.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| LEO Pharma Inc. | $88.48 | 07/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842194427 | CMS |
| Galderma Laboratories, L.P. | $20.11 | 07/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855276761 | CMS |
| SANOFI-AVENTIS U.S. LLC | $65.37 | 06/30/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843670635 | CMS |
| PFIZER INC. | $20.06 | 06/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832572429 | CMS |
| Novartis Pharmaceuticals Corporation | $20.15 | 06/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812696713 | CMS |
| Lilly USA, LLC | $28.81 | 06/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818645043 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $19.21 | 06/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849561837 | CMS |
| Regeneron Healthcare Solutions, Inc. | $25.59 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809581919 | CMS |
| GENZYME CORPORATION | $24.79 | 05/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843670643 | CMS |
| PFIZER INC. | $22.22 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832645611 | CMS |
| Lilly USA, LLC | $20.29 | 05/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818660783 | CMS |
| GENZYME CORPORATION | $21.73 | 04/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843670621 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $21.46 | 04/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851911175 | CMS |
| Regeneron Healthcare Solutions, Inc. | $26.33 | 04/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809581917 | CMS |
| TOLMAR Pharmaceuticals, Inc. | $18.04 | 04/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836498039 | CMS |
| PFIZER INC. | $20.33 | 04/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832653855 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $21.82 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851911173 | CMS |
| Lilly USA, LLC | $17.97 | 03/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818669915 | CMS |
| SANOFI-AVENTIS U.S. LLC | $24.97 | 03/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843670617 | CMS |
| AbbVie Inc. | $24.47 | 03/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794633379 | CMS |
| DERMIRA, INC. | $15.68 | 03/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 764403608 | CMS |
| PFIZER INC. | $22.30 | 03/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832560937 | CMS |
| Alexion Pharmaceuticals, Inc. | $22.80 | 02/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783116117 | CMS |
| Xeris Pharmaceuticals, Inc. | $16.34 | 02/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837423533 | CMS |
| Lilly USA, LLC | $12.54 | 01/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818642279 | CMS |
| PFIZER INC. | $19.01 | 01/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832572207 | CMS |
| Regeneron Healthcare Solutions, Inc. | $260.00 | 01/15/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809581895 | CMS |
| Regeneron Healthcare Solutions, Inc. | $260.00 | 01/15/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809581897 | CMS |
| Regeneron Healthcare Solutions, Inc. | $520.00 | 01/15/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809581899 | CMS |
| Regeneron Healthcare Solutions, Inc. | $520.00 | 01/15/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809581901 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1,040.00 | 01/15/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809581903 | CMS |
| Regeneron Healthcare Solutions, Inc. | $520.00 | 01/15/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809581905 | CMS |
| Regeneron Healthcare Solutions, Inc. | $520.00 | 01/15/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809581907 | CMS |
| Regeneron Healthcare Solutions, Inc. | $520.00 | 01/15/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809581909 | CMS |
| Regeneron Healthcare Solutions, Inc. | $260.00 | 01/15/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809581911 | CMS |
| Regeneron Healthcare Solutions, Inc. | $3,380.00 | 01/15/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809581913 | CMS |
| Regeneron Healthcare Solutions, Inc. | $104.00 | 01/15/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809581915 | CMS |
| GENZYME CORPORATION | $1,967.00 | 01/13/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843670599 | CMS |
| Regeneron Healthcare Solutions, Inc. | $25.35 | 01/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809581893 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $117,937.37 | 9 |
| PY2025 | Principal investigator | $884,331.45 | 126 |
| PY2024 | Recipient | $171,734.08 | 6 |
| PY2024 | Principal investigator | $638,630.46 | 249 |
| PY2023 | Principal investigator | $485,149.65 | 198 |
| PY2022 | Recipient | $11,033.02 | 26 |
| PY2022 | Principal investigator | $102,177.16 | 50 |
| PY2021 | Recipient | $599.27 | 2 |
| PY2021 | Principal investigator | $225,999.25 | 42 |
| PY2020 | Principal investigator | $161,571.53 | 38 |
| PY2019 | Principal investigator | $143,668.56 | 31 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
135 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $14,000.00 | 12/25/2025 | Non-covered Recipient Entity Pediatric Skin Research LLC | A LONGTERM DOUBLEBLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031 | No dispute reported | 06/30/2026 | 1228746725 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $658.00 | 12/24/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226129089 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $658.00 | 12/24/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226129093 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $658.00 | 12/24/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226129098 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $658.00 | 12/24/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226129102 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $658.00 | 12/24/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226129106 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $658.00 | 12/24/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226129111 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $541.00 | 12/24/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226129114 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $541.00 | 12/24/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226129118 |
| Principal investigator 1 | Incyte Corporation | $1,543.50 | 12/19/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576473 |
| Recipient | Nielsen BioSciences, Inc. | $111,668.37 | 12/15/2025 | Covered Recipient Physician | CFW-3A | No dispute reported | 06/30/2026 | 1215547454 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $30,621.00 | 12/15/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226126289 |
| Principal investigator 1 | PFIZER INC. | $6,331.15 | 12/11/2025 | Non-covered Recipient Entity Pediatric Skin Research LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228725548 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,819.00 | 12/08/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226126285 |
| Principal investigator 1 | ABBVIE INC. | $4,339.00 | 12/04/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202526824 |
| Principal investigator 1 | Incyte Corporation | $3,656.20 | 12/04/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576356 |
| Principal investigator 1 | Incyte Corporation | $3,429.00 | 12/04/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576362 |
| Principal investigator 1 | Incyte Corporation | $6,556.60 | 12/04/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576367 |
| Principal investigator 1 | Incyte Corporation | $4,930.60 | 12/04/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576477 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,602.70 | 12/04/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184269459 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,156.80 | 12/01/2025 | Non-covered Recipient Entity PEDIATRIC DERMATOLOGY OF MIAMI AT THE PEDIATRIC COE | A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled | No dispute reported | 06/30/2026 | 1190309142 |
| Principal investigator 1 | Incyte Corporation | $1,805.40 | 11/26/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576466 |
| Principal investigator 1 | Incyte Corporation | $1,465.20 | 11/25/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576296 |
| Principal investigator 1 | PFIZER INC. | $23,753.45 | 11/25/2025 | Non-covered Recipient Entity Pediatric Skin Research LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228727965 |
| Principal investigator 1 | PFIZER INC. | $1,065.00 | 11/19/2025 | Non-covered Recipient Entity Mercedes E Gonzalez MD | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228739985 |
| Principal investigator 1 | PFIZER INC. | $1,065.00 | 11/19/2025 | Non-covered Recipient Entity Mercedes E Gonzalez MD | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228748171 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $48,309.00 | 11/17/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226126276 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,901.80 | 11/17/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226126281 |
| Principal investigator 1 | Incyte Corporation | $1,815.30 | 11/13/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576462 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,838.50 | 11/10/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226126272 |
| Principal investigator 1 | Incyte Corporation | $2,542.50 | 11/07/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576303 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,371.61 | 11/07/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184257865 |
| Principal investigator 1 | ABBVIE INC. | $9,929.45 | 11/05/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202523071 |
| Principal investigator 1 | Incyte Corporation | $75.00 | 11/01/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576350 |
| Principal investigator 1 | PFIZER INC. | $31,611.30 | 10/29/2025 | Non-covered Recipient Entity Pediatric Skin Research LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228720749 |
| Recipient | GENZYME CORPORATION | $500.00 | 10/24/2025 | Covered Recipient Physician | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226127070 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $579.36 | 10/23/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184252798 |
| Principal investigator 1 | Incyte Corporation | $7,710.30 | 10/16/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576450 |
| Principal investigator 1 | Eli Lilly and Company | $8,620.00 | 10/14/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187887602 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 10/09/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202514497 |
| Principal investigator 1 | Incyte Corporation | $1,270.80 | 10/09/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576282 |
| Principal investigator 1 | Incyte Corporation | $1,805.40 | 10/09/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576455 |
| Principal investigator 1 | PFIZER INC. | $14,000.00 | 10/08/2025 | Non-covered Recipient Entity Pediatric Skin Research LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228729904 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $17,386.60 | 10/06/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226126248 |
| Principal investigator 1 | Incyte Corporation | $1,963.80 | 10/03/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576290 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,002.42 | 10/03/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184244813 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $13,538.00 | 09/29/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226126243 |
| Principal investigator 1 | Incyte Corporation | $310.50 | 09/23/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576270 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,580.00 | 09/23/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226126252 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $658.00 | 09/23/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226126255 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $658.00 | 09/23/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226126260 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $658.00 | 09/23/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226126264 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $541.00 | 09/23/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226126268 |
| Recipient | GENZYME CORPORATION | $500.00 | 09/17/2025 | Covered Recipient Physician | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226127061 |
| Principal investigator 1 | Incyte Corporation | $1,963.80 | 09/12/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576274 |
| Principal investigator 1 | PFIZER INC. | $16,400.00 | 09/09/2025 | Non-covered Recipient Entity Pediatric Skin Research LLC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228750502 |
| Principal investigator 1 | ABBVIE INC. | $2,458.55 | 09/04/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202509202 |
| Principal investigator 1 | Incyte Corporation | $3,429.00 | 09/04/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576264 |
| Principal investigator 1 | Incyte Corporation | $1,805.40 | 09/04/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576446 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,472.50 | 09/03/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226126238 |
| Recipient | PFIZER INC. | $940.00 | 08/29/2025 | Covered Recipient Physician | RITLECITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727769 |
| Principal investigator 1 | Incyte Corporation | $4,574.00 | 08/26/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576432 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $33,223.00 | 08/25/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226126234 |
| Principal investigator 1 | Incyte Corporation | $3,487.50 | 08/21/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576428 |
| Principal investigator 1 | Incyte Corporation | $3,041.10 | 08/14/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576252 |
| Principal investigator 1 | Incyte Corporation | $3,487.50 | 08/14/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576439 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $18,157.50 | 08/07/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH, LLC | A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis | No dispute reported | 06/30/2026 | 1248163786 |
| Principal investigator 1 | Incyte Corporation | $1,387.80 | 08/07/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576259 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $720.63 | 08/07/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184226337 |
| Principal investigator 1 | ABBVIE INC. | $6,651.75 | 08/06/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202502901 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $531.08 | 07/31/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184222974 |
| Principal investigator 1 | Incyte Corporation | $621.00 | 07/17/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576245 |
| Principal investigator 1 | Incyte Corporation | $18,296.00 | 07/17/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576422 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,834.00 | 07/14/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226126221 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $26,049.90 | 07/14/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226126226 |
| Principal investigator 1 | Incyte Corporation | $2,425.50 | 07/10/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576239 |
| Principal investigator 1 | Incyte Corporation | $1,543.50 | 07/04/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576414 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,953.13 | 07/04/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184213013 |
| Principal investigator 1 | ABBVIE INC. | $10,044.30 | 07/02/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202494171 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $31,852.00 | 07/02/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226126197 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,640.99 | 07/02/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants >=6 Months to <18 Years of Age With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1226126217 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $16,473.60 | 07/02/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226126230 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $10,000.00 | 06/23/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH, LLC | A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis | No dispute reported | 06/30/2026 | 1248163784 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $658.00 | 06/20/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226126189 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $658.00 | 06/20/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226126193 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $658.00 | 06/20/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226126202 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $541.00 | 06/20/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226126205 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $541.00 | 06/20/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226126209 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $541.00 | 06/20/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226126214 |
| Principal investigator 1 | Incyte Corporation | $1,963.80 | 06/19/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576233 |
| Principal investigator 1 | Incyte Corporation | $3,528.90 | 06/19/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576410 |
| Principal investigator 1 | Incyte Corporation | $1,077.30 | 06/12/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576227 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 06/03/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202489189 |
| Recipient | GENZYME CORPORATION | $500.00 | 05/29/2025 | Covered Recipient Physician | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226127057 |
| Recipient | GENZYME CORPORATION | $250.00 | 05/29/2025 | Covered Recipient Physician | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226127066 |
| Principal investigator 1 | Incyte Corporation | $2,309.40 | 05/28/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576342 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,325.49 | 05/28/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184199003 |
| Principal investigator 1 | Incyte Corporation | $1,077.30 | 05/22/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576329 |
| Principal investigator 1 | Incyte Corporation | $2,425.50 | 05/15/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576337 |
| Principal investigator 1 | Incyte Corporation | $2,274.30 | 05/08/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576322 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,611.60 | 05/08/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184193807 |
| Principal investigator 1 | ABBVIE INC. | $30,682.35 | 05/07/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202483955 |
| Recipient | PFIZER INC. | $330.00 | 05/06/2025 | Covered Recipient Physician | RITLECITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228722576 |
| Principal investigator 1 | Incyte Corporation | $1,077.30 | 04/28/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576317 |
| Principal investigator 1 | Incyte Corporation | $1,985.40 | 04/28/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576404 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $33,654.30 | 04/28/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226126181 |
| Principal investigator 1 | Incyte Corporation | $1,805.40 | 04/23/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576396 |
| Principal investigator 1 | Incyte Corporation | $2,465.10 | 04/15/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576307 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,985.20 | 04/15/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184183260 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,990.01 | 04/14/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants >=6 Months to <18 Years of Age With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1226126185 |
| Principal investigator 1 | ABBVIE INC. | $7,705.90 | 04/03/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202473037 |
| Principal investigator 1 | Incyte Corporation | $13,839.30 | 04/01/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576311 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $2,499.00 | 04/01/2025 | Covered Recipient Physician | NEUROPSYCHOLOGIC ASSESSMENTS OF DUPILUMAB-TREATED ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184117865 |
| Principal investigator 1 | Incyte Corporation | $13,595.40 | 03/25/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576391 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $658.00 | 03/24/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226126173 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $658.00 | 03/24/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226126177 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $869.04 | 03/19/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184174424 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $21,590.00 | 03/17/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226126169 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $48.28 | 03/11/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184170768 |
| Principal investigator 1 | ABBVIE INC. | $14,240.00 | 03/07/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | M17-380 - A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202461247 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $193.12 | 03/04/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184156632 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $750.00 | 03/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184117863 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $30,791.10 | 02/24/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226126165 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,875.78 | 02/18/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184154368 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,187.22 | 02/11/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184153050 |
| Principal investigator 1 | Amgen Inc. | $77,178.08 | 02/05/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis | No dispute reported | 06/30/2026 | 1246646409 |
| Principal investigator 1 | Eli Lilly and Company | $24,461.75 | 02/05/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187888128 |
| Principal investigator 1 | Amgen Inc. | $5,038.54 | 01/30/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH | A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis | No dispute reported | 06/30/2026 | 1246646413 |
| Principal investigator 1 | Incyte Corporation | $621.00 | 01/29/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576377 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $482.80 | 01/21/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184149152 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $16,164.00 | 01/21/2025 | Non-covered Recipient Entity Pediatric Skin Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226126161 |
| Principal investigator 1 | Incyte Corporation | $1,465.20 | 01/17/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576373 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $962.03 | 01/17/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184148223 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $962.03 | 01/07/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184146036 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $337.96 | 01/07/2025 | Non-covered Recipient Entity PEDIATRIC SKIN RESEARCH LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184146038 |